{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T07:14:53Z","timestamp":1769843693383,"version":"3.49.0"},"reference-count":36,"publisher":"Japanese Society for the Study of Xenobiotics","issue":"6","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2013]]},"DOI":"10.2133\/dmpk.dmpk-13-rg-004","type":"journal-article","created":{"date-parts":[[2013,5,6]],"date-time":"2013-05-06T23:00:33Z","timestamp":1367881233000},"page":"475-484","source":"Crossref","is-referenced-by-count":10,"title":["UDP-glucuronosyltransferase 2B15 (UGT2B15) Is the Major Enzyme Responsible for Sipoglitazar Glucuronidation in Humans: Retrospective Identification of the UGT Isoform by In Vitro Analysis and the Effect of UGT2B15*2 Mutation"],"prefix":"10.2133","volume":"28","author":[{"given":"Mitsuhiro","family":"Nishihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuto","family":"Hiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junzo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Asahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"900","reference":[{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0005","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2133\/dmpk.DMPK-11-RG-061","article-title":"Metabolic fate of sipoglitazar, a novel oral PPAR agonist with activities for PPAR-\u03b3, -\u03b1 and -\u03b4, in rats and monkeys and comparison with humans in vitro","volume":"27","author":"Nishihara","year":"2012","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0010","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1124\/dmd.111.040105","article-title":"An unusual metabolic pathway of sipoglitazar, a novel anti-diabetic agent: Cytochrome P450-catalyzed oxidation of sipoglitazar acyl glucuronide","volume":"40","author":"Nishihara","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0015","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/0091270012447121","article-title":"Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist, sipoglitazar","volume":"53","author":"Stringer","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0020","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00228-012-1382-7","article-title":"The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent","volume":"69","author":"Stringer","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0025","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/01.fpc.0000173483.13689.56","article-title":"Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily","volume":"15","author":"Mackenzie","year":"2005","journal-title":"Pharmacogenet. Genomics"},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0030","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3109\/03602530903210682","article-title":"UGT genomic diversity: beyond gene duplication","volume":"42","author":"Guillemette","year":"2010","journal-title":"Drug Metab. Rev."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0035","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/03602530903210716","article-title":"The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltrans- ferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential","volume":"42","author":"Miners","year":"2010","journal-title":"Drug Metab. Rev."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0040","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1517\/17425255.4.7.879","article-title":"Update on tools for evaluation of uridine diphosphoglucuronosyltransferase polymorphisms","volume":"4","author":"Argikar","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0168-8278(02)00306-9","article-title":"Combined polymorphisms in UDP-glucuronosyltransferases 1A1 and 1A6: implications for patients with Gilbert's syndrome","volume":"38","author":"Peters","year":"2003","journal-title":"J. Hepatol."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0050","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/cncr.21722","article-title":"Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy","volume":"106","author":"Massacesi","year":"2006","journal-title":"Cancer"},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0055","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/03602530600739835","article-title":"Pharmacogenetics of uridine diphospho- glucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan","volume":"38","author":"Nagar","year":"2006","journal-title":"Drug Metab. Rev."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0060","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1124\/jpet.104.067660","article-title":"UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver","volume":"310","author":"Court","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0065","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clpt.2005.02.006","article-title":"Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers","volume":"77","author":"Chung","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0070","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1210\/jc.2007-0359","article-title":"The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men","volume":"92","author":"Swanson","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0075","first-page":"497","article-title":"A polymorphism in the UDP-Glucuronosyltransferase 2B15 gene (D85Y) is not associated with prostate cancer risk","volume":"11","author":"Gsur","year":"2002","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0080","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00008571-199708000-00007","article-title":"Isolation and characterization of UGT2B15(Y85): a UDP- glucuronosyltransferase encoded by a polymorphic gene","volume":"7","author":"L\u00e9vesque","year":"1997","journal-title":"Pharmacoge- netics"},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0085","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/sj.tpj.6500171","article-title":"Pharmacogenomics of human UDP-glucuronosyltrans- ferase enzymes","volume":"3","author":"Guillemette","year":"2003","journal-title":"Pharmacogenomics J."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0090","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1080\/10826079408013459","article-title":"Determination of 4-methylumbelliferone and metabolites in Williams E medium and dog plasma by high performance liquid chromatography","volume":"17","author":"Lovdahl","year":"1994","journal-title":"J. Liq. Chromatogr"},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0095","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0076-6879(05)00007-8","article-title":"Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases","volume":"400","author":"Court","year":"2005","journal-title":"Methods Enzymol."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0100","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1124\/dmd.31.9.1125","article-title":"Evaluation of 3\u2032-azido-3\u2032- deoxythymidine, morphine, and codeine as probe substrates for UDP- glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism","volume":"31","author":"Court","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0105","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/dmd.32.4.413","article-title":"Human UDP-glucuronosyl- transferases: Isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid","volume":"32","author":"Uchaipichat","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0110","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1124\/dmd.30.11.1257","article-title":"Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9","volume":"30","author":"Court","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0115","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1124\/dmd.105.005108","article-title":"UDP- glucuronosyltransferase 2B7 is the major enzyme responsible for Gemcabene glucuronidation in human liver microsomes","volume":"33","author":"Bauman","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0120","doi-asserted-by":"crossref","first-page":"212","DOI":"10.2133\/dmpk.20.212","article-title":"Identification of human UDP-glucuronosyltrans- ferase isoform(s) responsible for the glucuronidation of 2-(4-chloro- phenyl)-5-(2-furyl)-4-oxazoleacetic acid (TA-1801A)","volume":"20","author":"Kaji","year":"2005","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0125","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.lfs.2010.07.001","article-title":"Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes","volume":"87","author":"Hanioka","year":"2010","journal-title":"Life Sci."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0130","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1124\/jpet.104.081968","article-title":"UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S)","volume":"313","author":"Krishnaswamy","year":"2005","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0135","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1124\/dmd.109.027227","article-title":"Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers","volume":"37","author":"Izukawa","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0140","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/dmd.108.023598","article-title":"Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction","volume":"37","author":"Ohno","year":"2009","journal-title":"Drug Metab. Dispos"},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0145","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3109\/00498254.2011.618954","article-title":"Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues","volume":"42","author":"Court","year":"2012","journal-title":"Xenobiotica"},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0150","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1210\/jc.2004-0331","article-title":"Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyl- transferases expressed in endometrium","volume":"89","author":"L\u00e9pine","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0155","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/S0006-2952(03)00064-9","article-title":"Cloning and characterisation of the first drug-metabolising canine UDP-glucuronosyltransferase of the 2B subfamily","volume":"65","author":"Soars","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0160","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1006\/abbi.1996.0320","article-title":"The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP- glucuronosyltransferase 1.1","volume":"332","author":"King","year":"1996","journal-title":"Arch. Biochem. Biophys"},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0165","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0003-9861(02)00084-X","article-title":"Isolation and characterization of a UDP-glucuronosyltransferase (UGT1A01) cloned from female rhesus monkey","volume":"402","author":"Dean","year":"2002","journal-title":"Arch. Biochem. Biophys."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0170","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1074\/jbc.M206136200","article-title":"Expression and characterization of recombinant human UDP-glucurono- syltransferases (UGTs)","volume":"278","author":"Kurkela","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0175","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00008571-199510000-00004","article-title":"Interindividual variability in the glucuronidation of (S)-oxazepam contrasted with that of (R)-oxazepam","volume":"5","author":"Patel","year":"1995","journal-title":"Pharmacogenetics"},{"key":"10.2133\/dmpk.DMPK-13-RG-004_bb0180","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1006\/abbi.1998.0750","article-title":"Determinants of UDP glucuronosyl- transferase membrane association and residency in the endoplasmic reticulum","volume":"356","author":"Meech","year":"1998","journal-title":"Arch. Biochem. Biophys."}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715304481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715304481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T12:36:45Z","timestamp":1498048605000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436715304481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"alternative-id":["S1347436715304481"],"URL":"https:\/\/doi.org\/10.2133\/dmpk.dmpk-13-rg-004","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2013]]}}}